NCT01388543已完成4 期
Genetic-determinants of Protease Inhibitor Pharmacology
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Day 7 Atazanavir Oral Clearance
研究概览
简要总结
This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal metabolizing genotype.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 to 55 years
- •Negative HIV screening antibody test
- •CYP3A5 expressor status, race, and sex fit an enrollment opening.
排除标准
- •Pregnant or breast-feeding
- •Medical history of
- •hepatitis B or C,
- •autoimmune disease,
- •active malignancy,
- •kidney disease including nephrolithiasis
- •Organ dysfunction manifested by
- •liver transaminases or
- •serum creatinine >1.25 times the upper limit of normal, or
- •any comprehensive metabolic test (except asymptomatic unconjugated hyperbilirubinemia), blood count, or lipid value > Grade I according to Division of AIDS (DAIDS) adverse drug event grading system (appendix).
- •Medical history of arrhythmias (including atrial fibrillation, atrioventricular block, and/or pacemaker)
- •Any QT interval abnormalities or other congenital arrhythmia syndromes on ECG or
- •Any ECG abnormality that in the opinion of the investigators would preclude entry into the study.
- •Medical history of any serious heart condition including:
- •congestive heart failure,
- •myopathies,
- •coronary artery disease, or
- •unexplained syncope.
- •Medical history of bleeding disorders (i.e., hemophilia)
- •Hyperlipidemia
- •Any prescription, herbal, recreational, or over-the-counter medication contraindicated with ritonavir or atazanavir including:
- •substrates/inhibitors/inducers of CYP3A/P-gp,
- •cardio-active medication, or
- •medications that alter the acid in the stomach. The study investigators will review each concurrent medication on a case-by-case basis.
- •Inability to refrain from grapefruit or grapefruit juice during the study.
- •Investigational drugs within the last 30 days.
- •Active alcohol / recreational drug abuse,
- •Inability to give informed consent.
- •A body mass index below 18.5 or above 34.
研究组 & 干预措施
CYP3A5 Expressors
Active Comparator
A pre-screening genetic test determines CYP3A5 expressor status
干预措施: Atazanavir (Drug)
CYP3A5 Non-expressors
Active Comparator
A pre-screening genetic test determines CYP3A5 non-expressor status
干预措施: Atazanavir (Drug)
结局指标
主要结局
Day 7 Atazanavir Oral Clearance
时间窗: Day 7
Measure atazanavir oral clearance in genetically-determined CYP3A5 expressors versus CYP3A5 non-expressors
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone ContraceptionPregnancyHIVAIDSNCT01667978University of Southern California35
已完成
4 期
Effect of Genetics on Metabolism of EfavirenzMetabolismNCT00245986National Institutes of Health Clinical Center (CC)350
招募中
不适用
Pharmacogenetic Determinants Of Treatment Response In ChildrenAll MalignanciesChildren Being Treated for Catastrophic IllnessNCT00730678St. Jude Children's Research Hospital8,800
已完成
不适用
Pharmacogenetics of Antiretroviral DrugsHIV InfectionsNCT00435656Cliniques universitaires Saint-Luc- Université Catholique de Louvain200
已完成
4 期
Genetic Determinants of ACEI Prodrug ActivationHealthy VolunteersNCT03051282University of Michigan21